Mr. Eric So reports

CYBIN ANNOUNCES RESULTS OF SHAREHOLDERS' MEETING

Cybin Inc. has released the voting results for each of the matters presented at the company's annual meeting of shareholders held on Aug. 15, 2022. There were 71 shareholders represented in person or by proxy at the meeting, holding 47,019,721 common shares, representing 28.3 per cent of Cybin's total issued and outstanding common shares as at the record date for the meeting. The voting results for each matter presented at the meeting is set out herein.

1. Appointment of auditor

Zeifmans LLP was appointed auditor of Cybin until the next annual meeting of shareholders at a remuneration to be fixed by the directors of Cybin.

      VOTING RESULTS FOR AUDITOR

     Votes for          Votes withheld

Number           %      Number        %   

43,128,097   92.51   3,493,074     7.49

2. Election of directors

Each of the nominees for election as director listed in Cybin's management information circular dated July 13, 2022, was elected as a director of Cybin for the ensuing year or until successors are elected or appointed.

        VOTING RESULTS FOR ELECTION OF DIRECTORS

                          Votes for         Votes withheld

                        Number       %      Number        %    
 
Theresa Firestone   20,199,337   98.50     308,536     1.50 
Grant Froese        20,146,515   98.24     361,358     1.76 
Paul Glavine        20,213,109   98.56     294,764     1.44 
Eric Hoskins        20,171,190   98.36     336,683     1.64 
Mark Lawson         20,150,317   98.26     357,556     1.74 
Eric So             18,097,784   88.23   2,415,089    11.77

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

We seek Safe Harbor.